Healthcare
Biden’s COVID Death Sentence
AP Images

Biden’s COVID Death Sentence

Countless people are unnecessarily dying of COVID because of the war against alternative treatments. The latest battlefront: the rationing of the monoclonal antibody therapy REGEN-GOV. ...
Selwyn Duke
Article audio sponsored by The John Birch Society

The “science,” which we’re supposed to “follow,” informs that perhaps 85 percent of COVID-19 victims could have been saved if a proper treatment protocol had been officially established. Early intervention is part of this, as it has long been understood that once a coronavirus patient exhibits advanced symptoms and must be hospitalized and ventilated, survivability greatly diminishes.

Enter drugs such as hydroxychloroquine and ivermectin, which have shown promise in mitigating SARS-CoV-2. Then there’s a newer option: the monoclonal antibody therapy REGEN-COV, which the Food and Drug Administration has authorized for use as a “post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals … who are at high risk for progression to severe COVID-19, including hospitalization or death,” as the agency puts it. Apparently a game-changer, the drug “has been shown to reduce hospitalization rates by 70 percent for high-risk COVID-19 patients treated within 10 days,” as even an August 26 Week article reprinted by liberal Yahoo! News concedes.

In light of this, what do you think the federal government’s REGEN-COV policy might be?


Sign in to Continue Reading
Please Login

JBS Member?

Sign in with your ShopJBS.org account.

The New American Digital Subscription Subscribe Now
  • 12 Issues Per Year
  • Digital Edition Access
  • Digital Insider Report
  • Exclusive Subscriber Content
  • Audio provided for all articles
  • Unlimited access to past issues
  • Cancel anytime.
  • Renews automatically
The New American Print+Digital Subscription Subscribe Now
  • 12 Issues Per Year
  • Print edition delivery (USA)
    *Available Outside USA
  • Digital Edition Access
  • Digital Insider Report
  • Exclusive Subscriber Content
  • Audio provided for all articles
  • Unlimited access to past issues
  • Cancel anytime.
  • Renews automatically